All In Biotech

Drug Trial Radar · NCT02390050

A Dose Range Finding Study to Evaluate the Effect of Bexagliflozin Tablets in Subjects With Type 2 Diabetes Mellitus

A Phase 2b, Multi-center, Double-blind, Placebo-controlled, Dose Range Finding Study to Evaluate the Effect of Bexagliflozin Tablets on HbA1c in Subjects With Type 2 Diabetes Mellitus

Last checked: Nov 20, 2026Latest source record: Jun 29, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 292 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

292

Actual

Start

May 12, 2015

Primary completion

Jun 3, 2016

Study completion Jun 3, 2016

Sponsor

Lead sponsor
TheracosIndustry
Sponsor type
Industry
First posted
Mar 17, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to investigate the effect of bexagliflozin in lowering hemoglobin A1c (HbA1c) levels in patients with type 2 diabetes mellitus (T2DM). Bexagliflozin is an orally administered drug for the treatment of T2DM and is classified as a Sodium Glucose co-Transporter 2 (SGLT2) Inhibitor. This study was to enroll both treatment naive and those subjects previously treated with one oral hypoglycemic agent (OHA). Approximately 320 subjects eligible for randomization was to receive bexagliflozin tablets, 5, 10, 20 mg or placebo, once daily for 12 weeks in an outpatient setting.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

  • Bexagliflozin tabletsDrug

    Bexagliflozin tablets are blue caplet-shaped, film-coated tablets that are intended for use in investigational studies in humans.

  • Bexagliflozin tablets, placeboDrug

    Bexagliflozin tablets, placebo, are blue caplet-shaped, film-coated tablets that are intended for use in investigational studies in humans.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in HbA1c After 12 Weeks of TreatmentTime frame: 12 weeks

Locations

50 sites in 2 countries. Site status is shown where the registry gives one.

  • Phoenix Medical Research Institute LLC

    Peoria, Arizona

  • Advanced Arizona Clinical Research

    Tucson, Arizona

  • Hope Clinical Research, LLC

    Canoga Park, California

  • Catalina Research Institute

    Chino, California

  • National Research Institute

    Huntington Park, California

  • Long Beach Clinical Trials

    Long Beach, California

  • Synergy San Diego

    National City, California

  • Northern California Research

    Sacramento, California

  • Artemis Institute for Clinical Research, LLC

    San Diego, California

  • Infosphere Clinical Research, Inc

    West Hills, California

  • M&O Clinical Research LLC

    Fort Lauderdale, Florida

  • AGA Clinical Trials

    Hialeah, Florida

  • Compass Research North

    Leesburg, Florida

  • Sweet Hope Research Specialty, Inc

    Miami Lakes, Florida

  • Sunshine Research Center

    Opa-locka, Florida

  • Compass Research LLC

    Orlando, Florida

  • Progressive Medical Research

    Port Orange, Florida

  • PICR Clinic

    Atlanta, Georgia

  • Sundance Clinical Research

    St Louis, Missouri

  • Premier Research Ltd

    Trenton, New Jersey

  • Regional Clinical Research, Inc

    Endwell, New York

  • Calabash Medical Center

    Calabash, North Carolina

  • Diabetes & Endocrinology Consultants PC

    Morehead City, North Carolina

  • PMG Research of Salisbury

    Salisbury, North Carolina

  • CTI Research

    Cincinnati, Ohio

  • Summit Research Group, LLC

    Stow, Ohio

  • Columbia Research Group, Inc.

    Portland, Oregon

  • Detweiler Family Medicine and Associate, P.C.

    Lansdale, Pennsylvania

  • North Myrtle Beach Family Practice

    Myrtle Beach, South Carolina

  • Global Medical Research

    DeSoto, Texas

  • Rockwood Medical Clinic

    Fort Worth, Texas

  • Wasatch Clinical Research

    Salt Lake City, Utah

  • Medical Corporation Hitomi-kai Motomachi Takatsuka Naika Clinic

    Yokohama Naka-ku, Kanagawa, Japan

  • Medical Corporation Hayashi katagihara Clinic

    Nishikyo-ku, Kyoto, Japan

  • Medical Corporation KEISEIKAI Kajiyama clinic

    Ukyou-ku, Kyoto, Japan

  • Ikeoka Medical Corp. Ikeoka Clinic

    Joto-ku, Osaka, Japan

  • Miyauchi Medical Center

    Takatsuki-shi, Osaka, Japan

  • Medical Corporation Senrichuo Ekimae Clinic

    Toyonaka-shi, Osaka, Japan

  • Medical Corporation Segawa Hospital

    Hikigun Ogawamachi, Saitama, Japan

  • Medical Corporation Yukeikai Asano Clinic

    Kawagoe-shi, Saitama, Japan

Showing 40 of 50 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.